US 11,884,630 B2
Heterocyclic compounds and their uses
Mingda Bi, Simi Valley, CA (US); and Robert Kuehl, San Francisco, CA (US)
Assigned to CYTOKINETICS, INC., South San Francisco, CA (US)
Filed by Cytokinetics, Inc., South San Francisco, CA (US)
Filed on Jun. 8, 2022, as Appl. No. 17/806,033.
Application 15/926,411 is a division of application No. 14/210,713, filed on Mar. 14, 2014, granted, now 9,951,015, issued on Apr. 24, 2018.
Application 17/806,033 is a continuation of application No. 16/579,360, filed on Sep. 23, 2019, granted, now 11,384,053.
Application 16/579,360 is a continuation of application No. 15/926,411, filed on Mar. 20, 2018, granted, now 10,421,726, issued on Sep. 24, 2019.
Claims priority of provisional application 61/785,763, filed on Mar. 14, 2013.
Prior Publication US 2022/0298114 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 213/75 (2006.01); A61K 9/20 (2006.01); A61K 31/496 (2006.01); A61K 47/38 (2006.01)
CPC C07D 213/75 (2013.01) [A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 31/496 (2013.01); A61K 47/38 (2013.01)] 22 Claims
 
1. A pharmaceutical formulation comprising:
about 30.65 mg of omecamtiv mecarbil dihydrochloride hydrate;
a control release agent;
a pH modifying agent comprising maleic acid, fumaric acid, tartaric acid, glutamic acid, or a combination thereof;
a filler; and
a lubricant.